Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib plus weekly paclitaxel in platinum-resistant ovarian cancer at risk of bowel obstruction
ISRCTN38690336Phase 2Completed
- Sponsor
- The University of Manchester
- Start
- Oct 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cediranib, paclitaxel and olaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by The University of Manchester. Primary endpoint: Safety of cediranib combination treatment. Started Oct 2017; status: completed.
02
Drugs
cediranibpaclitaxelolaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ISRCTN38690336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38690336.